Much more often than not, attempting to talk to friends or family members about their potential drug or alcohol abuse is a sensitive, challenging, and sometimes painful undertaking. It is natural for an individual who is addicted to drugs or alcohol, not to recognize the long-term consequences that cause pain and suffering to more people than just themselves. When seeking to help others overcome their addiction and the constant struggle with substance abuse, sometimes it is through those caring friends or family members that the user can finally find some relief2 by setting boundaries.

Med Ad News spoke with Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior Inc., about some of the barriers to patients seeking treatment for opioid use disorder, how to integrate treatment for opioid use disorder and infectious disease services, and the company’s efforts to provide treatments for those struggling with the disorder.

The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations (RICO) Act in May 2019 was sentenced to 33 months in federal prison.

Nektar Therapeutics withdrew the application for the company’s opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration panel unanimously voted against the drug’s approval.

Insights into former president Richard Sackler’s control of Purdue Pharma and his aggressive stance on marketing OxyContin were revealed when internal company documents were unsealed following a four-year court battle in Kentucky.

A federal judge partially overturned the convictions of Insys Therapeutics Inc.’s founder and three former executives accused of bribing doctors to prescribe an addictive opioid, but declined to disturb the remainder of the jury’s verdict.

The U.S. Department of Health and Human Services shelved a proposal to drastically cut the level of nicotine in cigarettes, Bloomberg reported citing a regulatory document.

OxyContin maker Purdue Pharma LP got court approval to reimburse millions of dollars in legal fees for states that back the company’s proposed $10 billion settlement of opioid lawsuits, but with a condition meant to help victims of the addiction crisis.

Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

Four large drug companies reached a last-minute $260 million legal settlement over their role in the U.S. opioid addiction epidemic, averting the first federal trial that was scheduled to start in Cleveland.